Alogliptin benzoate for management of type 2 diabetes

References

• KaragiannisTPaschosPPaletasKMatthewsDRTsapasADipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysisBMJ2012344e136922411919
   PubMed Web of Science ®Google Scholar
• FengJZhangZWallaceMBDiscovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IVJ Med Chem200750102297230017441705
   PubMed Web of Science ®Google Scholar
• BerhanABerhanYEfficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studiesBMC Endocr Disord2013131923452780
   PubMedGoogle Scholar
• SaishoYAlogliptin for the treatment of type 2 diabetesJ Symptoms Signs2014312634
   Google Scholar
• RendellMDrincicAAndukuriRAlogliptin benzoate for the treatment of type 2 diabetesExpert Opin Pharmacother201213455356322296609
   PubMed Web of Science ®Google Scholar
• WhiteJRAlogliptin for the treatment of type 2 diabetesDrugs Today (Barc)20114729910721431099
   PubMed Web of Science ®Google Scholar
• LeeBShiLKasselDBAsakawaTTakeuchiKChristopherRJPharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeysEur J Pharmacol20085891–330631418538760
   PubMed Web of Science ®Google Scholar
• HuanYJiangQLiuJ-LShenZ-FEstablishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitorsJ Pharmacol Toxicol Methods20157181225464020
   PubMed Web of Science ®Google Scholar
• NabenoMAkahoshiFKishidaHA comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active siteBiochem Biophys Res Commun2013434219119623501107
   PubMed Web of Science ®Google Scholar
• ChristopherRCovingtonPDavenportMPharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjectsClin Ther200830351352718405789
   PubMed Web of Science ®Google Scholar
• CovingtonPChristopherRDavenportMPharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetesClin Ther200830349951218405788
   PubMed Web of Science ®Google Scholar
• KarimACovingtonPChristopherRPharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjectsInt J Clin Pharmacol Ther2010481465820040339
   PubMed Web of Science ®Google Scholar
• BaettaRCorsiniAPharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differencesDrugs201171111441146721812507
   PubMed Web of Science ®Google Scholar
• GibbsJPFredricksonJBarbeeTQuantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy resultsJ Clin Pharmacol201252101494150522162539
   PubMed Web of Science ®Google Scholar
• DeFronzoRAFleckPRWilsonCAMekkiQEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled studyDiabetes Care200831122315231718809631
   PubMed Web of Science ®Google Scholar
• SeinoYFujitaTHiroiSHirayamaMKakuKEfficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension studyCurr Med Res Opin20112791781179221806314
   PubMed Web of Science ®Google Scholar
• PratleyREKipnesMSFleckPRWilsonCMekkiQEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapyDiabetes Obes Metab200911216717619125778
   PubMed Web of Science ®Google Scholar
• SeinoYHiroiSHirayamaMKakuKEfficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension studyJ Diabetes Invest201236517525
   PubMed Web of Science ®Google Scholar
• NauckMAEllisGCFleckPRWilsonCAMekkiQEfficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled studyInt J Clin Pract2009631465519125992
   PubMed Web of Science ®Google Scholar
• SeinoYMiyataYHiroiSHirayamaMKakuKEfficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension studyDiabetes Obes Metab2012141092793622583697
   PubMed Web of Science ®Google Scholar
• PratleyREFleckPWilsonCEfficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month studyDiabetes Obes Metab201416761362124400655
   PubMed Web of Science ®Google Scholar
• Del PratoSCamisascaRWilsonCFleckPDurability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year studyDiabetes Obes Metab201416121239124625132212
   PubMed Web of Science ®Google Scholar
• PratleyREReuschJEFleckPRWilsonCAMekkiQEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled studyCurr Med Res Opin200925102361237119650752
   PubMed Web of Science ®Google Scholar
• KakuKItayasuTHiroiSHirayamaMSeinoYEfficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension studyDiabetes Obes Metab201113111028103521682833
   PubMed Web of Science ®Google Scholar
• RosenstockJInzucchiSESeufertJFleckPRWilsonCAMekkiQInitial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetesDiabetes Care201033112406240820724648
   PubMed Web of Science ®Google Scholar
• DeFronzoRABurantCFFleckPWilsonCMekkiQPratleyREEfficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetesJ Clin Endocrinol Metab20129751615162222419732
   PubMed Web of Science ®Google Scholar
• Van RaalteDHvan GenugtenREEliassonBThe effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetesEur J Endocrinol2014170456557424421302
   PubMed Web of Science ®Google Scholar
• RosenstockJRendellMSGrossJLFleckPRWilsonCAMekkiQAlogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemiaDiabetes Obes Metab200911121145115219758359
   PubMed Web of Science ®Google Scholar
• KakuKMoriMKanooTKatouMSeinoYEfficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phaseExpert Opin Pharmacother201415152121213025190226
   PubMed Web of Science ®Google Scholar
• WhiteWBCannonCPHellerSRAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med2013369141327133523992602
   PubMed Web of Science ®Google Scholar
• ArodaVRHenryRRHanJEfficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic reviewClin Ther201234612471258e122222608780
   PubMed Web of Science ®Google Scholar
• CraddyPPalinH-JJohnsonKIComparative effectiveness of ddipeptidylpeptidase-4 iinhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonDiabetes Ther20145114124664619
   PubMed Web of Science ®Google Scholar
• MarfellaRBarbieriMGrellaRRizzoMRNicolettiGFPaolissoGEffects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuationsJ Diabetes Complications2010242798319261490
   PubMed Web of Science ®Google Scholar
• SignorovitchJEWuEQSwallowEKantorEFanLGruenbergerJBComparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trialsClin Drug Invest2011319665674
   PubMed Web of Science ®Google Scholar
• SakamotoMNishimuraRIrakoTTsujinoDAndoKUtsunomiyaKComparison of vildagliptin twice daily vs sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study)Cardiovasc Diabetol2012119222867630
   PubMed Web of Science ®Google Scholar
• DeFronzoRAStonehouseAHHanJWintleMERelationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trialsDiabet Med201027330931720536494
   PubMed Web of Science ®Google Scholar
• EspositoKChiodiniPCapuanoAMaiorinoMBellastellaGGiuglianoDBaseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitorsEndocrine2014461435124248503
   PubMed Web of Science ®Google Scholar
• KimYGHahnSOhTJKwakSHParkKSChoYMDifferences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysisDiabetologia201356469670823344728
   PubMed Web of Science ®Google Scholar
• KimYGHahnSOhTJParkKSChoYMDifferences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysisDiabetes Obes Metab2014161090090924655583
   PubMed Web of Science ®Google Scholar
• EspositoKChiodiniPMaiorinoMIBellastellaGCapuanoAGiuglianoDGlycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trialsBMJ Open201446e005442
   PubMed Web of Science ®Google Scholar
• RosenstockJWilsonCFleckPAlogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year studyDiabetes Obes Metab2013151090691423531118
   PubMed Web of Science ®Google Scholar
• BronMWilsonCFleckPA post hoc analysis of HbA1c, hypoglycemia, and weight change outcomes with alogliptin vs glipizide in older patients with type 2 diabetesDiabetes Ther2014552153425424968
   PubMed Web of Science ®Google Scholar
• PratleyREMcCallTFleckPRWilsonCAMekkiQAlogliptin use in elderly people: a pooled analysis from phase 2 and 3 studiesJ Am Geriatr Soc200957112011201919793357
   PubMed Web of Science ®Google Scholar
• NakamuraYInagakiMShimizuTLong-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year studyNephron Clin Pract20131231–2465123774306
   PubMedGoogle Scholar
• MoritohYTakeuchiKAsakawaTKataokaOOdakaHChronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob miceEur J Pharmacol20085882-332533218499100
   PubMed Web of Science ®Google Scholar
• KawashimaSMatsuokaTAKanetoHEffect of alogliptin, pioglitazone and glargine on pancreatic beta-cells in diabetic db/db miceBiochem Biophys Res Commun2011404153454021144823
   PubMed Web of Science ®Google Scholar
• ZhangXWangZHuangYWangJEffects of chronic administration of alogliptin on the development of diabetes and beta-cell function in high fat diet/streptozotocin diabetic miceDiabetes Obes Metab201113433734721205126
   PubMed Web of Science ®Google Scholar
• YinHParkSYWangXJEnhancing pancreatic beta-cell regeneration in vivo with pioglitazone and alogliptinPLoS One201386e6577723762423
   PubMed Web of Science ®Google Scholar
• BosiEEllisGCWilsonCAFleckPRAlogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group studyDiabetes Obes Metab201113121088109621733058
   PubMed Web of Science ®Google Scholar
• JurczykADiiorioPBrostowinDImproved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rgamma(null) mice treated with alogliptinDiabetes Metab Syndr Obes Target Ther20136493499
   PubMedGoogle Scholar
• FoleyJEBunckMCMoller-GoedeDLBeta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trialDiabetologia20115481985199121547496
   PubMed Web of Science ®Google Scholar
• EliassonBMoller-GoedeDEeg-OlofssonKLowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled studyDiabetologia201255491592522237690
   PubMed Web of Science ®Google Scholar
• MonamiMLamannaCDesideriCMMannucciEDPP-4 inhibitors and lipids: systematic review and meta-analysisAdv Ther2012291142522215383
   PubMed Web of Science ®Google Scholar
• ShahZKampfrathTDeiuliisJALong-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxisCirculation2011124212338234922007077
   PubMed Web of Science ®Google Scholar
• TaNNSchuylerCALiYLopes-VirellaMFHuangYDPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient miceJ Cardiovasc Pharmacol201158215716621558879
   PubMed Web of Science ®Google Scholar
• YangDNakajoYIiharaKKataokaHYanamotoHAlogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal miceBrain Res2013151710411323602966
   PubMed Web of Science ®Google Scholar
• NodaYMiyoshiTOeHAlogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary reportCardiovasc Diabetol201312823298374
   PubMed Web of Science ®Google Scholar
• MegaCde LemosETValaHDiabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat)Exp Diabetes Res2011201116209222203828
   PubMedGoogle Scholar
• NakashimaSMatsuiTTakeuchiMYamagishiSILinagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axisHorm Metab Res2014461071772124710699
   PubMed Web of Science ®Google Scholar
• LiuWJXieSHLiuYNDipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic ratsJ Pharmacol Exp Ther2012340224825522025647
   PubMed Web of Science ®Google Scholar
• VavrinecPHenningRHLandheerSWVildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in Zucker diabetic fatty ratCurr Vasc Pharmacol201412683684424066937
   PubMed Web of Science ®Google Scholar
• FujitaHTaniaiHMurayamaHDPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1alpha in type 2 diabetic patients with incipient nephropathyEndocr J201461215916624225429
   PubMed Web of Science ®Google Scholar
• SakataKHayakawaMYanoYEfficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetesDiabetes Metab Res Rev201329862463023861159
   PubMed Web of Science ®Google Scholar
• SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317132623992601
   PubMed Web of Science ®Google Scholar
• AvogaroAFadiniGPThe effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complicationsDiabetes Care201437102884289425249673
   PubMed Web of Science ®Google Scholar
• WhiteWBPratleyRFleckPCardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitusDiabetes Obes Metab201315766867323489301
   PubMed Web of Science ®Google Scholar
• MonamiMDicembriniIMannucciEDipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trialsNutr Metab Cardiovasc Dis201424768969724793580
   PubMed Web of Science ®Google Scholar
• CliftonPDo dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?Clin Ther201436122072207925453730
   PubMed Web of Science ®Google Scholar
• BrownNJByiersSCarrDMaldonadoMWarnerBADipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedemaHypertension200954351652319581505
   PubMed Web of Science ®Google Scholar
• SaishoYItohHDipeptidyl peptidase-4 inhibitors and angioedema: a class effect?Diabet Med2013304e149e15023323612
   PubMed Web of Science ®Google Scholar
• MonamiMDicembriniIMartelliDMannucciESafety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trialsCurr Med Res Opin201127Suppl 3576422106978
   PubMed Web of Science ®Google Scholar
• NauckMAA critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risksDiabetes Care20133672126213223645884
   PubMed Web of Science ®Google Scholar
• ElashoffMMatveyenkoAVGierBElashoffRButlerPCPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1- based therapiesGastroenterology2011141115015621334333
   PubMed Web of Science ®Google Scholar
• SinghSChangHYRichardsTMWeinerJPClarkJMSegalJBGlucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control studyJAMA Intern Med2013173753453923440284
   PubMed Web of Science ®Google Scholar
• YabeDKuwataHKanekoMUse of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugsDiabetes Obes Metab8222014 Epub ahead of print
   PubMed Web of Science ®Google Scholar
• GiordaCSacerdoteCNadaEMarafettiLBaldiIGnaviRIncretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studiesEndocrine8222014 Epub ahead of print
   Web of Science ®Google Scholar
• ScheenAAlogliptin: concern about hepatotoxicity?Clin Pharmacokinet201453111057105925336393
   PubMed Web of Science ®Google Scholar
• ButlerAEJansonJBonner-WeirSRitzelRRizzaRAButlerPCBeta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetesDiabetes200352110211012502499
   PubMed Web of Science ®Google Scholar
• YoonKHKoSHChoJHSelective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in KoreaJ Clin Endocrinol Metab20038852300230812727989
   PubMed Web of Science ®Google Scholar
• SakurabaHMizukamiHYagihashiNWadaRHanyuCYagihashiSReduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patientsDiabetologia2002451859611845227
   PubMed Web of Science ®Google Scholar
• RahierJGuiotYGoebbelsRMSempouxCHenquinJCPancreatic beta-cell mass in European subjects with type 2 diabetesDiabetes Obes Metab200810Suppl 4324218834431
   PubMed Web of Science ®Google Scholar
• SkarforsETSelinusKILithellHORisk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in UppsalaBMJ199130368057557601932936
   PubMedGoogle Scholar
• ErikssonKFLindgardeFPoor physical fitness, and impaired early insulin response but late hyperinsulinaemia, as predictors of NIDDM in middle-aged Swedish menDiabetologia19963955735798739917
   PubMed Web of Science ®Google Scholar
• WeyerCBogardusCMottDMPratleyREThe natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitusJ Clin Invest1999104678779410491414
   PubMed Web of Science ®Google Scholar
• HaffnerSMMiettinenHGaskillSPSternMPDecreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-AmericansDiabetes19954412138613917589843
   PubMed Web of Science ®Google Scholar
• LyssenkoVAlmgrenPAnevskiDPredictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetesDiabetes200554116617415616025
   PubMed Web of Science ®Google Scholar
• TabakAGJokelaMAkbaralyTNBrunnerEJKivimakiMWitteDRTrajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II studyLancet200937396822215222119515410
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupUK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive diseaseDiabetes19954411124912587589820
   PubMed Web of Science ®Google Scholar
• LevyJAtkinsonABBellPMMcCanceDRHaddenDRBeta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet StudyDiabet Med19981542902969585393
   PubMed Web of Science ®Google Scholar
• SaishoYTanakaKAbeTShimadaAKawaiTItohHEffect of obesity on declining beta cell function after diagnosis of type 2 diabetes: a possible link suggested by cross-sectional analysisEndocr J201259318719522156325
   PubMed Web of Science ®Google Scholar
• SaishoYKouKTanakaKAssociation between beta cell function and future glycemic control in patients with type 2 diabetesEndocr J201360451752323268927
   PubMed Web of Science ®Google Scholar
• SaishoYTanakaKAbeTShimadaAKawaiTItohHGlycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetesDiabetol Int201123146153
   Google Scholar
• SaishoYBeta cell dysfunction: its critical role in prevention and management of type 2 diabetesWorld J Diabetes20156110912425685282
   PubMed Web of Science ®Google Scholar
• MuscelliECasolaroAGastaldelliAMechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetesJ Clin Endocrinol Metab20129782818282622685234
   PubMed Web of Science ®Google Scholar
• Solis-HerreraCTriplittCGarduno-GarciaJDAdamsJDefronzoRACersosimoEMechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer studyDiabetes Care20133692756276223579178
   PubMed Web of Science ®Google Scholar
• MullerWAFaloonaGRAguilar-ParadaEUngerRHAbnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestionN Engl J Med197028331091154912452
   PubMed Web of Science ®Google Scholar
• Del PratoSFeltonAMMunroNNestoRZimmetPZinmanBImproving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goalInt J Clin Pract200559111345135516236091
   PubMed Web of Science ®Google Scholar
• DeFronzoRAAbdul-GhaniMAPreservation of beta-cell function: the key to diabetes preventionJ Clin Endocrinol Metab20119682354236621697254
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care201538114014925538310
   PubMed Web of Science ®Google Scholar
• GarberAJAbrahamsonMJBarzilayJIAACE comprehensive diabetes management algorithm 2013Endocr Pract201319232733623598536
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation Guideline Development GroupGlobal guideline for type 2 diabetesDiabetes Res Clin Pract2014104115224508150
   PubMed Web of Science ®Google Scholar
• PhungOJScholleJMTalwarMColemanCIEffect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetesJAMA2010303141410141820388897
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med2006355232427244317145742
   PubMed Web of Science ®Google Scholar
• LevinDBellSSundRPioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysisDiabetologia201458349350425481707
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: a meta-analysisAm J Med2007120871371917679131
   PubMed Web of Science ®Google Scholar
• HutchinsVZhangBFleurenceRLKrishnarajahGGrahamJA systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetesCurr Med Res Opin20112761157116821466277
   PubMed Web of Science ®Google Scholar
• KurozumiAOkadaYMoriHAraoTTanakaYEfficacy of α-glucosidase inhibitors combined with dipeptidyl-peptidase-4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoringJ Diabetes Invest201344393398
   PubMed Web of Science ®Google Scholar
• JabbourSAHardyESuggJParikhSStudy 10 GroupDapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled StudyDiabetes Care201437374075024144654
   PubMed Web of Science ®Google Scholar
• WengJLiYXuWEffect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trialLancet200837196261753176018502299
   PubMed Web of Science ®Google Scholar
• PennartzCSchenkerNMengeBASchmidtWENauckMAMeierJJChronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetesDiabetes Care20113492048205321775756
   PubMed Web of Science ®Google Scholar
• GersteinHCMillerMEByingtonRPEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• LipskaKJRossJSWangYNational trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011JAMA Intern Med201417471116112424838229
   PubMed Web of Science ®Google Scholar
• VijanSSussmanJBYudkinJSHaywardRAEffect of patients’ risks and preferences on Health gains with plasma glucose level lowering in type 2 diabetes mellitusJAMA Intern Med201417481227123424979148
   PubMed Web of Science ®Google Scholar
• RazIRiddleMCRosenstockJPersonalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors’ Expert ForumDiabetes Care20133661779178823704680
   PubMed Web of Science ®Google Scholar
• HsuWCBoykoEJFujimotoWYPathophysiologic differences among Asians, native Hawaiians, and other Pacific Islanders and treatment implicationsDiabetes Care20123551189119822517940
   PubMed Web of Science ®Google Scholar
• KodamaKTojjarDYamadaSTodaKPatelCJButteAJEthnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysisDiabetes Care20133661789179623704681
   PubMed Web of Science ®Google Scholar
• KouKSaishoYSatohSYamadaTItohHChange in beta cell mass in Japanese non-diabetic obese individualsJ Clin Endocrinol Metab20139893724373023766518
   PubMed Web of Science ®Google Scholar